June 9, 2026 10:33 AM EDTUpdated 01:56 PM R&DPharma Trodelvy misses again in lung cancer, but Gilead and Merck have an HIV success to soften the blow Ayisha Sharma News Reporter Gilead Sciences and Merck have reported a hit and a miss for their Phase 3 HIV and lung cancer programs, respectively, but investors were largely … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
91 words · extracted 1mo agoread original ↗
comments(0)
5-min edit window · permanent after that